Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.

Abstract:

:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashion in addition to a previously optimized levodopa/carbidopa (Sinemet) regimen. Disability was recorded hourly at home by patients 3 days weekly during the 2-week baseline and the 6-week treatment period. Disability during the "on" state was assessed each week by examination. Mean hourly self-assessment of gait improved in 28 of 50 patients (56%) receiving deprenyl (mean degree of improvement 0.25 points on a 0-2 scale) and in 14 of 46 (30.4%) taking placebo (mean 0.15). Mean hourly overall symptom control improved in 29 (58%) taking deprenyl (mean 0.34) and in 12 (26.1%) taking placebo (mean 0.15) (p less than 0.01 for each parameter). No significant improvement occurred in the objective quality of the "on" state with deprenyl. Mean daily Sinemet dosage decreases were 17% in the deprenyl group and 7% in the placebo group. Adverse effects included nausea, light-headedness, dyskinesias, and hallucinations, all of which abated after the Sinemet dose was reduced. We conclude that deprenyl is of moderate benefit in a majority of patients with symptom fluctuations complicating PD and is generally well tolerated.

journal_name

Clin Neuropharmacol

authors

Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

doi

10.1097/00002826-198802000-00004

subject

Has Abstract

pub_date

1988-02-01 00:00:00

pages

45-55

issue

1

eissn

0362-5664

issn

1537-162X

journal_volume

11

pub_type

临床试验,杂志文章,随机对照试验
  • Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.

    abstract::Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

    更新日期:1998-09-01 00:00:00

  • Astroglial cells: glucocorticoid target cells in the brain.

    abstract::Glutamine synthetase (GS), an enzyme localized in astroglial cells in the brain, is directly implicated in brain detoxification. An ontogenic study of GS activity was performed in homogenates from four distinct brain areas in comparison with the respective astrocytes obtained in primary cultures. GS was induced by hyd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Tardy M,Rolland B,Fages C,Caldani M

    更新日期:1984-01-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.

    abstract::Tolcapone, a central and peripheral catechol O-methyltransferase (COMT) inhibitor, reduces the conversion of L-Dopa into 3-O-methyl-Dopa (3-OMD), thus leading to more stable and sustained L-Dopa plasma levels. This study was designed to evaluate the effects of acute and 6-week tolcapone administration on L-Dopa pharma...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199901000-00005

    authors: Napolitano A,Del Dotto P,Petrozzi L,Dell'Agnello G,Bellini G,Gambaccini G,Bonuccelli U

    更新日期:1999-01-01 00:00:00

  • Central action of cinnarizine and flunarizine: a saccadic eye movement study.

    abstract::The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single ora...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199410000-00003

    authors: Casucci G,Di Costanzo A,Riva R,Albani F,Bonavita V,Tedeschi G

    更新日期:1994-10-01 00:00:00

  • Piracetam in the treatment of different types of myoclonus.

    abstract::Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198812000-00006

    authors: Obeso JA,Artieda J,Quinn N,Rothwell JC,Luquin MR,Vaamonde J,Marsden CD

    更新日期:1988-12-01 00:00:00

  • Gabapentin treatment for muscle cramps: an open-label trial.

    abstract::To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200001000-00008

    authors: Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

    更新日期:2000-01-01 00:00:00

  • Paroxetine-associated hypereosinophilia may clinically resemble a panic attack.

    abstract::Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31823da9a8

    authors: Yasui-Furukori N,Sato Y,Kato H,Kaneko S

    更新日期:2012-01-01 00:00:00

  • Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection.

    abstract::Interferon (IFN) is the most widely prescribed drug of choice for chronic hepatitis B infection, which is a common health problem in our country. Therapy with IFN-alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and depressive disorders. In this case report,...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200405000-00002

    authors: Atasoy N,Ustundag Y,Konuk N,Atik L

    更新日期:2004-05-01 00:00:00

  • Unusual case of levodopa-responsive camptocormia in a patient with negative dopamine transporter scan and normal DYT 5 gene.

    abstract:OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000024

    authors: Oravivattanakul S,Abboud H,Fernandez H,Itin I

    更新日期:2014-03-01 00:00:00

  • Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.

    abstract::Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199508000-00009

    authors: Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

    更新日期:1995-08-01 00:00:00

  • Cognitive improvement in clinical trials with nootropic drugs: when can it be expected and how to clarify its meaning.

    abstract::In order to have a correct evaluation of the activity of a nootropic drug, the criteria adopted for the choice of patients to be included in the clinical trials and the methods used to clarify the meaning of changes observed on cognitive tasks are reported. The results of a clinical trial with the nootropic oxiracetam...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Gainotti G,Benedetti N,Caltagirone C,Nocentini U

    更新日期:1986-01-01 00:00:00

  • Preclamol and parkinsonian fluctuations.

    abstract::Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomo...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Pirtosek Z,Merello M,Carlsson A,Stern G

    更新日期:1993-12-01 00:00:00

  • Pregabalin in zolpidem dependence and withdrawal.

    abstract::Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820a3b5a

    authors: Oulis P,Nakkas G,Masdrakis VG

    更新日期:2011-03-01 00:00:00

  • Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

    abstract::Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, fo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.wnf.0000240956.49315.be

    authors: Fernandez HH,Chen JJ

    更新日期:2007-05-01 00:00:00

  • Donepezil Improved Cognitive Deficits in a Patient With Neurosyphilis.

    abstract::A large number of patients with neurosyphilis present dementia with a progressive course and psychiatric symptoms such as depression, mania, and psychosis. Despite prompt and proper antibiotic treatment, the recovery is often incomplete, especially when tissue damage has occurred. We reported a patient with persisted ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000094

    authors: Wu YS,Lane HY,Lin CH

    更新日期:2015-07-01 00:00:00

  • Successful Treatment of Brachial Plexopathy Due to Herpes Zoster Infection With Intravenous Immunoglobulin.

    abstract:OBJECTIVE:The aim of this study was to report the case of a male patient with Parkinson disease who developed brachial plexopathy (BP) due to varicella-zoster virus, which was successfully treated with human immunoglobulin. METHOD:We report the case of a 75-year-old male subject with a diagnosis of Parkinson disease w...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000195

    authors: Sáenz-Farret M,Sandoval-Rodríguez V,Paz-Navarro CE,Zúñiga-Ramírez C

    更新日期:2017-01-01 00:00:00

  • Treatment of primary progressive freezing of gait with high doses of selegiline.

    abstract::We report the case of a 76-year-old, right-handed woman with progressive primary freezing of gait. Despite several therapeutic strategies, she continued to worsen to the point that she became confined to a wheelchair. Treatment with selegiline in doses up to 20 mg/d led to marked improvement of the gait disorder. This...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200601000-00007

    authors: Zúñiga C,Lester J,Cersósimo MG,Díaz S,Micheli FE

    更新日期:2006-01-01 00:00:00

  • Place of dexfenfluramine in the management of obesity.

    abstract::The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Guy-Grand BJ

    更新日期:1988-01-01 00:00:00

  • Neurobiology and clinical pharmacology of obsessive-compulsive disorder.

    abstract::Obsessive-compulsive disorder (OCD) is a brain disorder with recognizable periods of onset, course, familial occurrence, epidemiology, phenomenology, and treatment response. Several manifestations of pathophysiology are beginning to be defined, although they may represent intermediate pathophysiology rather than prima...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200107000-00002

    authors: Micallef J,Blin O

    更新日期:2001-07-01 00:00:00

  • Platelet supersensitivity to thrombin stimulation in depression: a possible mechanism for the association with cardiovascular mortality.

    abstract::The mortality risk associated with cardiovascular disease is significantly increased in patients with major depression and panic disorder. The mechanism of this phenomenon is unclear. Thrombin is responsible for platelet aggregation and shape change, and it plays a significant role in the development of thromboembolic...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200007000-00002

    authors: Berk M,Plein H

    更新日期:2000-07-01 00:00:00

  • Beneficial effect of fluoxetine in a case of sporadic hyperekplexia.

    abstract::We studied a 67-year-old woman with a sporadic form of hyperekplexia, who experienced 8-10 excessive startle responses to unexpected stimuli per month. Therapy with fluoxetine had a definite beneficial effect. This finding supports the hypothesis that serotonergic mechanisms play a role in this disorder. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200005000-00006

    authors: Sechi G,Sotgiu S,Valenti MP,Pitzolu MG,Peterlongo P,Larizza L,Rosati G

    更新日期:2000-05-01 00:00:00

  • De Novo Myoclonic Status Epilepticus After Benzodiazepine Withdrawal.

    abstract::Myoclonic status epilepticus (MSE) in patients without epilepsy, or de novo MSE, is a rare condition associated with several acute symptomatic etiologies, including drugs and toxins. We describe a 94-year-old woman with Alzheimer dementia and long use of mirtazapine 30 mg/d and alprazolam 1 mg/d who developed MSE appr...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000283

    authors: Vicente Ferreira Naves P,Calderaro M,Caboclo LO

    更新日期:2018-07-01 00:00:00

  • Parkinsonism in Patients With Chronic Hepatitis C Treated With Interferons: Case Reports and Review of the Literature.

    abstract::Interferons are a set of cytokines that activate antiviral responses by the body's immune cells and have been a mainstay of treatment of hepatitis C. Well-known neuropsychiatric effects of interferons include depression, irritability, and impaired concentration. A condition reported rarely in association with this tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0000000000000120

    authors: Wangensteen KJ,Krawitt EL,Hamill RW,Boyd JT

    更新日期:2016-01-01 00:00:00

  • Medical treatment of patients with infantile spasms.

    abstract::Infantile spasms are the main feature in West syndrome, an age-related epilepsy syndrome that affects 1 in every 2,000-4,000 infants. The authors provide a comprehensive review of the literature about infantile spasms and their therapy. In the United States, the drug of choice for infantile spasms, at least the crypto...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-200203000-00001

    authors: Mikati MA,Lepejian GA,Holmes GL

    更新日期:2002-03-01 00:00:00

  • Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study.

    abstract::A correlation was found among the degree of memory loss, intellectual impairment, the quantity of senile plaques, and a decrease in choline acetyltransferase and acetylcholinesterase activity in patients affected by senile dementia of the Alzheimer type. In this study, patients were subjected to a series of computeriz...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198312000-00005

    authors: Agnoli A,Martucci N,Manna V,Conti L,Fioravanti M

    更新日期:1983-01-01 00:00:00

  • Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.

    abstract::Duloxetine is a serotonin-noradrenaline reuptake inhibitor that is effective in the treatment of major depressive disorder (MDD) and chronic pain. The safety of duloxetine has been shown by many previous studies. We report a patient who experienced visual hallucinations after taking duloxetine. The patient experienced...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182a124cb

    authors: Tomita T,Yasui-Furukori N,Kaneko S

    更新日期:2013-09-01 00:00:00

  • Memory deficits of aged male rats can be improved by pyrimidine nucleosides and n-acetyl-glutamine.

    abstract::The pyrimidine nucleosides uridine (URI) and cytidine (CYT), alone or associated with n-acetyl-glutamine (NAG), were injected acutely or subchronically to aged (26 months old) male rats of the Sprague-Dawley strain. Learning and memory abilities of the animals were studied with tests of avoidance behavior. The acquisi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199008000-00002

    authors: Drago F,D'Agata V,Valerio C,Spadaro F,Raffaele R,Nardo L,Grassi M,Freni V

    更新日期:1990-08-01 00:00:00

  • Falls and Parkinson's disease.

    abstract::One hundred patients with Parkinson's disease (PD) and five patients with progressive supranuclear palsy were questioned about the frequency, circumstances, and consequences of falling. Parkinsonian symptoms were scored using the unified rating scale. Thirty-eight percent of parkinsonian patients fell, and 13% fell mo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198904000-00003

    authors: Koller WC,Glatt S,Vetere-Overfield B,Hassanein R

    更新日期:1989-04-01 00:00:00

  • Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

    abstract:OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013e31827db49b

    authors: Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

    更新日期:2013-01-01 00:00:00

  • Treatment of psychogenic polydipsia with acetazolamide: a report of 5 cases.

    abstract:OBJECTIVE:Psychogenic polydipsia occurs frequently in patients with chronic psychiatric illness and is often unmanageable. We herein report 5 patients in whom acetazolamide was trialed for this symptom. METHODS:We encountered a case in which polydipsia improved with incidental administration of acetazolamide. We then ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318205070b

    authors: Takagi S,Watanabe Y,Imaoka T,Sakata M,Watanabe M

    更新日期:2011-01-01 00:00:00